Q1. Why was it a good idea to choose the "complex and evolving" area of ccRcc as one of the two FTO preclinicals when there are so many other tissues in which the role of FTO overexpression is more straightforward?
Q2. Is it important for RAC to demonstrate the relevance of Zantrene to synthetic lethality?
Pillar 1 - FTO (new thread), page-1769
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
-0.035(2.11%) |
Mkt cap ! $276.9M | |||
| Open | High | Low | Value | Volume |
| $1.67 | $1.67 | $1.62 | $172.5K | 105.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5995 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 4075 | 1 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |